Results and discussion
Using a yeast-based signal sequence trap [9] , we identified a human umbilical vein endothelial cell cDNA that encodes a new TNF-related ligand, which we termed hGITRL. The cDNA encodes a 177 amino-acid polypeptide ( Figure 1a) , with a calculated mass of 20 kDa, and with a type 2 transmembrane topology that is characteristic of the TNF family [1] . The hGITRL extracellular domain (ECD) shows sequence identity particularly to TNF (21%), Fas ligand (FasL; 21%), Apo2 ligand (Apo2L; 18%), and lymphotoxin α (LTα; 18%) ( Figure 1b) . We analyzed the expression of hGITRL mRNA in human tissues using reverse transcriptase PCR (RT-PCR). We detected the highest level of hGITRL mRNA expression in small intestine, ovary, testis and kidney, and lower levels or no expression in other tissues ( Figure 1c ).
To identify a receptor that might recognize hGITRL, we searched human expressed sequence tag (EST) DNA databases for sequences with homology to the ECDs of TNFR family members. One such EST enabled us to isolate from human bone marrow a cDNA that encodes a 241 amino-acid TNFR homolog with a type 1 transmembrane protein topology and a calculated mass of 26 kDa; we termed this receptor hGITR (Figure 2a) . It shows the highest sequence identity (59% overall; 57% extracellular, 64% intracellular) to a recently discovered murine TNFR homolog, mGITR [4] . Like mGITR, hGITR contains three cysteine-rich domains (CRDs); CRD3 has three cysteines, rather than the more typical four or six cysteines of the TNFR family. In addition, several stretches of sequence in the intracellular domain (ICD) are conserved between hGITR and mGITR, but not in their next-closest relatives, CD27 and 4-1BB (CDw137). The degree of identity between hGITR and mGITR (~60%) is similar to that which exists in general between human and mouse orthologs of other TNFR family members [1, 2] . Further, hGITR displays only 14-28% sequence identity to other known members of the human TNFR family. We surmise that the newly identified cDNA encodes a human ortholog of mGITR. Notable differences between hGITR and mGITR are the presence of eight compared with five cysteines in CRD1, and of one compared with four N-linked glycosylation sites in the ECD (Figure 2a ). Northern blot hybridization analyses of several tissues did not reveal hGITR mRNA (data not shown), but quantitative RT-PCR indicated hGITR mRNA expression in peripheral blood leukocytes (PBLs), bone marrow, spleen, thymus, lung and brain, and relatively lower levels in other tissues (Figure 2b ). Peripheral blood T cells expressed low levels of hGITR transcript, but responded to phytohemagglutinin or anti-CD3 antibody treatment by substantial induction of hGITR mRNA (Figure 2c ). which located hGITRL to chromosome 1q23. FasL also maps to 1q23 [5] , and another TNF homolog, OX40 ligand, maps to 1q25 [10] . The hGITR gene showed linkage to Stanford marker SHGC-4723, which located hGITR to 1p36.3, a region that also encodes the TNFR homologs Apo3/DR3 [6] , TNFR2, CD30, OX40 and 4-1BB [1] .
To test whether hGITR and hGITRL interact, we generated a soluble histidine-tagged protein consisting of the hGITRL ECD [11] and created soluble immunoglobulin fusion proteins (immunoadhesins) [12] containing the ECD of hGITR, mGITR or of other TNFR homologs. In a microtiter plate assay, hGITRL bound to hGITR-immunoadhesin, but not to mGITR, TNFR1, TNFR2, DR5 or Fas immunoadhesins (Figure 3a) . In a coprecipitation assay, radiolabeled hGITRL bound to hGITR-immunoadhesin, but not to DR3, DR4, DR5, TNFR1, TNFR2, or Fas immunoadhesins (Figure 3b ). Full-length hGITRL, displayed on the surface of transfected 293 cells, bound to hGITR-immunoadhesin, but not to TNFR1, HVEM or DcR1 immunoadhesins (Figure 3c ). Given that hGITRL transcripts were readily detectable in human umbilical vein endothelial cells by RT-PCR (data not shown), we postulated that endothelial cells might express hGITRL on their surface. Consistent with this notion, hGITR-immunoadhesin showed specific, though limited, binding to cultured human umbilical vein endothelial cells (Figure 3d ).
To explore the signaling functions of hGITRL, we tested its ability to regulate the transcription factor NF-κB, which is stimulated by TNF [13] . Transfection of hGITR into 293 cells resulted in significant NF-κB activation, as measured by reporter-gene induction ( Figure 4a) ; coexpression of hGITRL greatly enhanced this response. Dominantnegative mutant forms of TRAF2 [7, 14] or of NIK [8] substantially inhibited NF-κB activation by hGITRL-hGITR ( Figure 4b ). By contrast, dominant-negative mutants of the TNFR1-interacting protein RIP [15, 16] or of the interleukin-1 and Toll receptor adaptors TRAF6 [17] and MyD88 [18, 19] did not block NF-κB activation by hGITRL-hGITR. Thus, hGITRL activates NF-κB through hGITR by engaging a pathway that appears to involve TRAF2 and NIK, similar to the pathway that TNF engages through TNFR2. Given that NF-κB activation has anti-apoptotic effects in many cell types [19] , and that T-cell activation induces hGITR expression, we tested the effect of hGITRL and hGITR on activationinduced cell death (AICD) [4] . Anti-CD3 antibody triggered AICD in human Jurkat T leukemia cells ( Figure 4c) ; transfection of the cells with hGITRL or hGITR inhibited the response, and coexpression of ligand and receptor provided nearly complete protection against AICD.
We have identified a ligand-receptor pair that belongs to the human TNF and TNFR superfamilies. Several observations indicate that the new human receptor, hGITR, is an ortholog of mGITR [4] . First, there is substantial sequence conservation between the two proteins, particularly in the 
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ICD, which mediates signaling. Second, neither receptor mRNA is detectable in tissues by northern hybridization, but low mRNA levels of each are detectable in lymphoid tissues by RT-PCR. Third, T-cell receptor stimulation induces a marked increase in mRNA expression of each gene. Fourth, both receptors confer protection against AICD in T-cell lines. The fact that hGITRL did not bind to mGITR is not inconsistent with the suggestion that hGITR and mGITR are orthologs, because several TNF family members exhibit species-specific binding to their receptors [1] .
We detected the hGITRL mRNA mainly in peripheral tissues; stimulation of peripheral blood T cells did not induce hGITRL mRNA expression (data not shown). In addition, soluble hGITR bound to vascular endothelial cells, which suggests that these cells express hGITRL on their surface. We observed low levels of hGITR mRNA expression, mainly in lymphoid tissues; however, peripheral blood T cells expressed abundant hGITR upon stimulation, which implicates hGITR in T-cell function. In contrast to the induction of mGITR by dexamethasone in a mouse T-cell hybridoma [4] , we did not find induction of hGITR by dexamethasone in peripheral blood T cells (data not shown). Further studies will be needed to investigate whether hGITR is regulated by glucocorticoids in thymic T cells. Consistent with the ability of hGITRL to activate NF-κB, cotransfection of the ligand and receptor protected human Jurkat T cells against AICD. These results, together with the expression data, suggest that hGITRL and hGITR may modulate T-lymphocyte survival in peripheral tissues and perhaps during interaction with the vascular endothelium.
Materials and methods

Isolation and expression of hGITRL and hGITR cDNA
The hGITRL cDNA was isolated from a human umbilical vein endothelial cell library probed with the 32 P-labeled oligonucleotide 5′-AATGGCT-TATATTTAATTTATGGCCAAGTGGCTCCCAATGCAAACTACAA. The
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Figure 2
Primary structure and mRNA expression of hGITR (TNFRSF18, Genbank accession number AF1253040). Relative RNA expression Fas  DR4  DR5  TNFR1  TNFR2  DR3  hGITR  Control hGITR cDNA was isolated from a human bone marrow library probed with the oligonucleotide 5′-GAGGAGTGCTGTTCCGAGTGGGACTG-CATGTGTGTCCAGC. Soluble hGITRL ECD (amino acids 52-177) was expressed in Escherichia coli as an amino-terminally His 10 -tagged molecule [11] . The hGITR or mGITR ECD (amino acids 1-161 or 1-149) immunoadhesins [12] were expressed in insect cells.
Analysis of mRNA expression
Expression of hGITRL mRNA was analyzed by RT-PCR using firststrand cDNA from tissues and primers that amplify a 450 bp product from the coding region of hGITRL. Expression of hGITR mRNA was assayed by quantitative RT-PCR on a Taqman instrument (ABI) as described [20] , using PCR primers that amplify a 90 bp product from the coding sequence of hGITR. The authenticity of the PCR products was confirmed by Southern blot hybridization to the corresponding cDNA (data not shown).
NF-κB assay
Human 293 cells (2 × 10 5 ) were transfected by calcium phosphate precipitation with 0.5 µg of plasmid pGL3-ELAM.tk, which carries a firefly luciferase gene driven by an NF-κB-responsive element from the E-selectin gene. In addition, 0.05 µg of a Renilla luciferase reporter plasmid was transfected for monitoring transfection efficiency (Pharmacia), together with the indicated expression plasmids (0.1 µg hGITR; 0.5 µg other expression vectors), and carrier plasmid pRK5D to maintain constant DNA amounts. After 24 h, cells were harvested and luciferase activity was assayed as recommended (Pharmacia). Expression vectors encoding dominant-negative mutants are described elsewhere for TRAF2 (87-501) [14] , NIK (K429A, K430A) [8] , RIP (559-671) [16] , TRAF6 (289-522) [17] and MyD88 [18] .
Analysis of AICD
Human Jurkat T cells (2 × 10 6 ) were transfected by Superfect (Qiagen) with a total of 5 µg plasmid DNA. After 18 h, the cells were washed, divided in half, and plated in wells coated with either control or anti-CD3 antibody (40 µg/ml) (Pharmingen). Apoptosis was assayed 24 h later by FACS analysis of annexin V binding (Pharmingen) as described [11] . 
